A new nanomedicine study explores whether iron oxide-loaded vesicles from bone marrow stem cells can be tracked by MRI while still influencing inflamed endothelial cells.

Paper: MRI-trackable USPIO-loaded hBM-MSC derived extracellular vesicles as nanoplatform for endothelial inflammation. Image Credit: ART-ur / Shutterstock
A paper published in the journal Nanomedicine: Nanotechnology, Biology, and Medicine investigated the MRI detectability, physicochemical characteristics, and biological activity of ultrasmall superparamagnetic iron oxide nanoparticles (USPIO)-loaded human bone marrow (hBM)-mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) in an inflammatory human umbilical vein endothelial cell (HUVEC) model.
Importance of MSC-EVs
EVs derived from MSCs (MSC-EVs) have gained considerable attention as cell-free therapeutic agents for modulating pathological processes linked with vascular dysfunction, tissue injury, and inflammation.
MSC-EVs consist of diverse bioactive molecules that can influence recipient-cell signaling and exert immunomodulatory, pro-angiogenic, tissue-reparative, and anti-inflammatory effects. These properties make MSC-EVs suitable for developing therapeutic strategies to restore cellular homeostasis within inflammatory microenvironments.
Endothelial cells have attracted particular interest among the cell types influenced by MSC-EVs. Endothelial dysfunction is associated with cerebrovascular, neurodegenerative, and cardiovascular diseases.
Endothelial activation promotes blood-brain barrier and neurovascular dysfunction, as well as vascular inflammation. For MSC-EV-based therapies, modulating endothelial inflammation is a relevant target.
Clinical Translation of MSC-EVs
Clinical translation is limited in part by the difficulty of assessing tissue localization, biodistribution, and persistence after MSC-EV administration in a noninvasive manner.
Imaging can be added to therapeutic EVs to relate vesicle localization to biological activity in vivo. For instance, USPIOs have been incorporated into EVs to detect them using MRI.
Loading EVs with USPIOs can provide MRI contrast, but nanoparticle incorporation may alter EV membrane properties, cargo integrity, interactions with recipient cells, or physicochemical characteristics.
USPIO-loaded hBM-MSC-derived EVs
In this work, researchers investigated an imaging-enabled hBM-MSC-EV platform based on USPIO, focusing on biological activity in an inflammatory HUVEC model.
They evaluated USPIO cellular uptake and the physicochemical characteristics of USPIO-loaded EVs (USPIO-EVs), along with their MRI detectability.
In cytokine-activated HUVECs, researchers assessed the biological activity of USPIO-EVs using nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and vascular cell adhesion molecule 1 (VCAM-1) as markers of endothelial inflammatory activation.
The objective of the study was to evaluate whether USPIO-loaded hBM-MSC-derived EVs could modulate endothelial inflammatory responses and remain detectable by MRI.
By combining EV characterization with functional testing, the study provides proof of concept for MRI-detectable USPIO-EV preparations that retain measurable biological activity.
hBM-MSCs were cultured at 5% carbon dioxide and 37 °C in low-glucose Dulbecco's Modified Eagle's Medium (DMEM), with fetal bovine serum and standard culture supplements.
Different concentrations of USPIO-citrate were used to treat hBM-MSCs for 24 h to select the exposure concentration. After 24 h of exposure, hBM-MSCs were washed three times with phosphate-buffered saline (PBS) and placed in serum-free starvation medium for 24 h to release USPIO-EVs.
Researchers quantified interleukin-6 (IL-6) secretion to assess whether USPIO treatment elicited a pro-inflammatory response in MSCs. HUVECs were cultured in a 1:1 mixture of Ham's F12 and low-glucose DMEM, with fetal bovine serum and standard supplements, at 5% carbon dioxide and 37 °C.
To induce an inflammatory response, HUVECs were treated with 50 ng/mL each of TNF-α and IFN-γ for 16 h, then recovered for 48 h with USPIO-EVs or PBS. Researchers quantified iron content in hBM-MSCs treated with USPIO; characterized and isolated USPIO-EVs; determined the MRI contrast properties of USPIO-MSCs, USPIO-EVs, and USPIO; and evaluated the anti-inflammatory properties of USPIO-EVs.
Study Findings
Reduced NF-κB and VCAM-1 mRNA expression indicated that USPIO-loaded EVs modulated endothelial inflammatory responses. Citrate coating was used to minimize nanoparticle aggregation and improve colloidal stability under cell culture conditions.
Transmission electron microscopy displayed spherical, homogeneous 5 nm nanoparticles, without evident aggregation. At 100 μg/mL USPIO-citrate, hBM-MSC viability was about 85% of untreated controls, and basal IL-6 secretion was not increased. USPIO uptake was 7.35 ± 0.10 pg Fe/cell at this concentration.
USPIO-EVs had slightly lower modal and mean diameters than EVs from untreated cells. Their size distribution was broader. CD81, CD9, and pan-tetraspanin signals were lower, while CD63 was largely comparable with control EVs.
In EVs isolated from 10.5 × 106 hBM-MSCs, a total of 4.82 μg Fe was detected, showing that some nanoparticle-associated iron was present in the isolated EV fraction. The measurements establish an association with this fraction, but do not show that all detected iron was enclosed within intact EVs.
MRI measurements in agar phantoms confirmed magnetic contrast in USPIO, USPIO-loaded MSCs, and USPIO-EV preparations.
Rising USPIO concentrations produced progressive decreases in T2* signal intensity and T2 relaxation times. Prussian blue/UV-Vis analysis estimated that 6.2% of the iron taken up by the MSCs was associated with the isolated EV fraction, compared with 12.9% by MRI. The authors said nanoparticle clustering may raise the MRI estimate.
After USPIO-EV exposure, HUVECs contained intracellular iron-positive deposits, showing transfer of iron-containing material but not proving uptake of intact EVs.
Tumor necrosis factor-α and interferon-γ induced strong NF-κB and VCAM-1 expression in the inflammatory model, whereas under basal conditions, USPIO-EVs did not activate these markers.
In cytokine-stimulated HUVECs, USPIO-EV treatment reduced VCAM-1 and NF-κB mRNA expression to about 60% of stimulated control levels. Protein-level effects, endothelial function, and comparison with unloaded MSC-EVs were not assessed.
The findings of this study support further investigation of USPIO-EVs in an endothelial inflammatory context as MRI-detectable USPIO-EV preparations with biological activity. MRI detection was shown in agar phantoms rather than living organisms, leaving in vivo biodistribution, persistence, efficacy, and MRI tracking after administration untested.
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.